ASCO 2015 Highlights

Precision Medicine and Immunotherapy Highlighted at ASCO 2018
By Wayne Kuznar
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Interest in personalizing medicine in oncology is growing, so the American Society of Clinical Oncology (ASCO) titled its theme for the 2018 presidential address at the annual meeting, "Delivering Discoveries: Expanding the Reach of Precision Medicine."
Read Article
New Clues to Mismatch Repair and PD-1/PD-L1 Status and Survival in Patients with Gastric or Esophageal Cancer
By Charles Bankhead
Gastrointestinal Cancers
Web Exclusives
San Francisco, CA—Understanding the complex relationship between the PD-1 receptor, its ligand 1 (PD-L1), and mismatch repair deficiency (dMMR) status may help to improve treatment outcomes in patients with resectable gastric and esophageal cancer, according to a retrospective tissue-based analysis.
Read Article
Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma
By Wayne Kuznar
Cholangiocarcinoma
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—A greater understanding of the biology of cholangiocarcinoma, including differences between intrahepatic versus extrahepatic cholangiocarcinoma, is driving the development of new therapeutic options that have shown promising results in advanced stages of this difficult-to-treat cancer.
Read Article
NCCN Panel Debates Cancer Care in Value-Based Healthcare Models
By Wayne Kuznar
NCCN Annual Conference, Value in Oncology
Web Exclusives
Experts at this roundtable discussion addressed high patient costs, achieving greater value in oncology care, and the desire for access to comparative data.
Read Article
What the Next Generation of Cancer Biomarkers May Involve
What the Next Generation of Cancer Biomarkers May Involve
By Sanjiv S. Agarwala, MD
ASCO 2018 Insights
Videos
Dr Sanjiv Agarwala predicts that the cancer biomarkers of the future may be “mobile biomarkers,” meaning measures of the tumor microenvironment or immune response that change with therapy and may be able to determine treatment efficacy.
Read Article
How MSI and TMB Factor into Current Biomarker Testing Panels
How MSI and TMB Factor into Current Biomarker Testing Panels
By Sanjiv S. Agarwala, MD
ASCO 2018 Insights
Videos
Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types.
Read Article
Best Practices in How Oncologists and Pathologists Can Work Together to Optimize Biomarker Testing for Their Patients with Cancer
Best Practices in How Oncologists and Pathologists Can Work Together to Optimize Biomarker Testing for Their Patients with Cancer
By Sanjiv S. Agarwala, MD
ASCO 2018 Insights
Videos
Read Article
Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries
Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries
By Sanjiv S. Agarwala, MD
ASCO 2018 Insights
Videos
Dr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy.
Read Article

Page 113 of 330

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.